Danielle Brill
Stock Analyst at Truist Securities
(4.10)
# 585
Out of 5,182 analysts
106
Total ratings
46.32%
Success rate
16.17%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Maintains: Buy | $68 → $64 | $26.47 | +141.78% | 2 | Apr 14, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $515 → $505 | $308.51 | +63.69% | 4 | Apr 13, 2026 | |
| APGE Apogee Therapeutics | Initiates: Hold | $83 | $86.49 | -4.04% | 1 | Mar 18, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $17 | $9.50 | +78.95% | 1 | Mar 18, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $63 → $110 | $87.16 | +26.20% | 3 | Mar 9, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $68.85 | +20.55% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $86 → $95 | $74.52 | +27.48% | 4 | Feb 25, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $169 → $140 | $128.04 | +9.34% | 9 | Feb 17, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $39.51 | -3.82% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $28.75 | +108.70% | 3 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $16 → $22 | $28.62 | -23.13% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $45 | $31.05 | +44.93% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $190 | $128.64 | +47.70% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $9.29 | +405.92% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $426.01 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $20.80 | +15.38% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $17.90 | +190.50% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $19.94 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $53.81 | +46.83% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $8.62 | +108.82% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $20.98 | +614.97% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $180.67 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $783.74 | -22.81% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.30 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $54.26 | -7.85% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $24.43 | +108.76% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $5.71 | +1,651.31% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $69.22 | - | 9 | Sep 18, 2023 |
Maze Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $68 → $64
Current: $26.47
Upside: +141.78%
Alnylam Pharmaceuticals
Apr 13, 2026
Maintains: Buy
Price Target: $515 → $505
Current: $308.51
Upside: +63.69%
Apogee Therapeutics
Mar 18, 2026
Initiates: Hold
Price Target: $83
Current: $86.49
Upside: -4.04%
Climb Bio
Mar 18, 2026
Initiates: Buy
Price Target: $17
Current: $9.50
Upside: +78.95%
Dianthus Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $63 → $110
Current: $87.16
Upside: +26.20%
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $68.85
Upside: +20.55%
BridgeBio Pharma
Feb 25, 2026
Maintains: Buy
Price Target: $86 → $95
Current: $74.52
Upside: +27.48%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $169 → $140
Current: $128.04
Upside: +9.34%
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $39.51
Upside: -3.82%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $28.75
Upside: +108.70%
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $28.62
Upside: -23.13%
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $31.05
Upside: +44.93%
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $128.64
Upside: +47.70%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $9.29
Upside: +405.92%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $426.01
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $20.80
Upside: +15.38%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $17.90
Upside: +190.50%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $19.94
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $53.81
Upside: +46.83%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.62
Upside: +108.82%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $20.98
Upside: +614.97%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $180.67
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $783.74
Upside: -22.81%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.30
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $54.26
Upside: -7.85%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $24.43
Upside: +108.76%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $5.71
Upside: +1,651.31%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $69.22
Upside: -